ArticleAdvances in urology2026
Are Big Prostates a Challenge? Correlation Between Prostate Volume and Detection Rate in Fusion Biopsy of the Prostate.
Article in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Are Big Prostates a Challenge? Correlation Between Prostate Volume and Detection Rate in Fusion Biopsy of the Prostate.Advances in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the relationship between prostate cancer (PCa) detection rates and prostate volume. Prostate volume may influence the diagnostic performance of MRI-ultrasound (MRI-US) fusion biopsy. Enlarged prostate glands present specific challenges, including reduced specificity of prostate-specific antigen (PSA), anatomical alterations of the transition zone, and potential limitations in biopsy accuracy. Material and Methods: We retrospectively analyzed 1300 consecutive patients with elevated PSA and/or abnormal digital rectal examination (DRE) who underwent MRI-US fusion-guided biopsy between 2014 and 2023. Patients were stratified into five prostate volume groups (< 30, 30-54.9, 55-79.9, 80-119.9, and ≥ 120 mL). For PI-RADS-based analyses, three volume categories (< 50, 50-100, and > 100 mL) were applied. Detection rates for overall PCa and clinically significant prostate cancer (csPCa) were assessed. Results: A total of 1203 patients were included. The overall cancer detection rate was 62.0% (746/1203), with 39.5% (475/1203) classified as clinically significant. Detection rates decreased significantly with increasing prostate volume, from 82.3% in prostates < 30 mL to 28.9% in prostates ≥ 120 mL ( Conclusion: Prostate volume is an independent determinant of cancer detection in MRI-US fusion biopsy. Larger prostate glands are associated with significantly reduced detection rates across all PI-RADS categories. These findings highlight the need to consider prostate volume in diagnostic decision-making and to adapt biopsy strategies in patients with enlarged prostates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.